[NH2:1][CH2:2][C@H:3]1[C@H:8]([CH3:9])[CH2:7][CH2:6][CH2:5][N:4]1[C:10]([C:12]1N=C(C)S[C:16]=1[C:17]1[CH:22]=[CH:21][C:20](F)=C[CH:18]=1)=[O:11].CC1C=CC([N:35]2[N:39]=[CH:38][CH:37]=[N:36]2)=C(C=1)C(O)=O>>[NH2:1][CH2:2][C@H:3]1[C@H:8]([CH3:9])[CH2:7][CH2:6][CH2:5][N:4]1[C:10]([C:12]1[CH:16]=[C:17]([CH3:18])[CH:22]=[CH:21][C:20]=1[N:35]1[N:39]=[CH:38][CH:37]=[N:36]1)=[O:11]The title compound was prepared following the same general protocol as described for rac-trans-(2-(aminomethyl)-3-methylpiperidin-1-yl)(5-(4-fluorophenyl)-2-methylthiazol-4-yl)methanone in Example A65 using 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid. MS (ESI) 314 (M+H).